High insulin and high androgens tend to reinforce each other, so reading one without the other leaves half the picture. The sections below cover the mechanism, who it affects, which markers belong on the same blood draw, and when a result is worth raising with a clinician.
Insulin resistance means muscle, liver and fat cells respond less strongly to insulin, so the pancreas secretes more of it to keep blood glucose steady. In polycystic ovary syndrome, the consequence that matters most is the extra insulin itself, not only the glucose number.
Insulin is the hormone that moves glucose out of the bloodstream into cells and tells the liver to slow its own glucose output. When that signal lands less effectively, the pancreas compensates by releasing more. Glucose can stay inside the standard range for a long time while insulin climbs quietly in the background. That is the single most useful thing to understand about this topic. A normal fasting glucose on its own says very little about how much insulin was needed to produce it.
Research suggests that insulin resistance sits at the centre of the metabolic picture in polycystic ovary syndrome rather than at its edge 1. Reduced insulin sensitivity in this condition has been described across several tissues, including skeletal muscle, adipose tissue and liver, with each contributing in a different way 2. Work on the underlying mechanism describes a signalling problem downstream of the insulin receptor in polycystic ovary syndrome that is distinct from the pattern seen with weight gain alone 3.
The practical translation is simple. In people with PCOS, a glucose result cannot rule insulin resistance in or out by itself, and an insulin measurement adds information that glucose alone cannot provide.
Because insulin acts directly on the ovary and indirectly on the liver, raising both androgen production and the share of testosterone that circulates in its free, active form.
Inside the ovary, the theca cells produce androgens in response to signals from the pituitary gland. Insulin appears to amplify that response, so the same pituitary signal yields more androgen output when insulin is high. Research suggests that higher insulin levels are associated with elevated androgen levels in polycystic ovary syndrome, and that this relationship is one of the central features of the condition 4.
The second route runs through the liver. Sex hormone binding globulin, usually shortened to SHBG, is the carrier protein that binds testosterone and keeps a portion of it inactive. Higher insulin is associated with lower SHBG production by the liver, which raises the free fraction of testosterone even when the total amount has not changed much 3.
That is why two people can have very similar total testosterone results and very different symptoms. One has a healthy SHBG and most of that testosterone is bound. The other has a low SHBG, a larger free fraction, and more androgen activity at the skin and hair follicle.
There is also a feedback element. Research on the mechanism describes the relationship between androgen excess and insulin resistance as reciprocal rather than one directional, with each capable of reinforcing the other 3. None of this confirms a diagnosis on its own. It explains why a hormone panel and a metabolic panel read better together than separately.
Yes. Reduced insulin sensitivity in polycystic ovary syndrome is not confined to people carrying excess weight, and lean women with the condition have been found to show it as well, independent of body weight 5.
This matters because it changes who gets tested. A lean person with irregular cycles and androgen symptoms is less likely to be offered a metabolic workup, simply because the visual cue that usually prompts one is absent. Yet the signalling problem described in polycystic ovary syndrome appears to be intrinsic to the condition and separate from the insulin resistance that accompanies weight gain 3.
Excess body fat does not cause the pattern, but it can amplify it. Adipose tissue is one of the tissues where insulin signalling is altered in polycystic ovary syndrome, alongside muscle and liver 2. So two things are true at once. A lean person can have meaningful insulin resistance, and additional body fat can make an existing tendency more pronounced.
If you recognise yourself in the symptom picture but have always been told your weight rules it out, that is a reasonable thing to raise with a clinician and ask for the numbers rather than the assumption.
The honest answer is that the sequence is not settled, and for testing purposes it does not need to be. Both ends of the loop are measurable, and both are worth measuring.
The long standing model holds that insulin resistance comes first and the pancreas raises insulin output to compensate, with the excess insulin then driving ovarian androgen production 5. A more recent reappraisal suggests the relationship between high insulin and insulin resistance in polycystic ovary syndrome may be less one directional than that, with insulin secretion itself potentially contributing rather than only responding 6.
What this means for you is narrow but useful. Waiting to establish which came first delays nothing worth delaying, because the same markers are informative either way. Insulin, glucose, androgens and SHBG together describe where you currently sit, and repeating them over time describes the direction of travel.
It also means that a result sitting toward the upper end of a reference range is information rather than noise. Compensation works until it does not, and the period when insulin is rising while glucose still reads ordinary is exactly the period a fasting insulin result can describe.
The signs most often reported in this context are cycle irregularity, androgen related skin and hair changes, and skin darkening in body folds. None of them confirms anything on its own, and each has other possible explanations.
Commonly reported features include the following.
The skin and hair features in that list reflect androgen activity at the hair follicle, and elevated androgen levels are associated with insulin resistance in polycystic ovary syndrome. That association is why a metabolic panel is often informative in someone presenting with androgen symptoms, even when the presenting concern is purely cosmetic.
The last two items are the least specific. Energy dips after meals have many causes, including sleep debt, meal size and simple habit. They are worth noting as context for a clinician rather than treating as proof of anything by themselves.
Fasting insulin measures how much insulin is circulating in the blood after an overnight fast, which reflects how hard the pancreas is working to hold glucose steady. The full picture of what the test is, how it is run and how to read a single result lives on the Fasting Insulin page.
In brief, typical lab reference ranges run from roughly 2 to 18 µU/mL, and FitScript's optimal range is 2 to 5 µU/mL. Optimal ranges are optimization targets rather than diagnostic cut-offs, so a result above an optimal range is not a finding in itself. Reference ranges vary by lab, age and sex, so read your own result against the range printed on your own report and bring it to a clinician for interpretation.
There is no single blood test that defines insulin resistance, so assessment usually combines several measures taken at the same draw. Fasting insulin and fasting glucose are the common starting pair, because each is uninformative about the other.
From those two values, labs often calculate an index called HOMA-IR, which expresses the glucose and insulin pair as one number so that trends are easier to follow across repeat tests. HbA1c adds a slower moving view of glucose exposure over recent months. In some situations a clinician will arrange a glucose tolerance test with insulin measured alongside glucose, which shows the response to a challenge rather than the resting state. Reviews of how insulin resistance is evaluated in polycystic ovary syndrome describe this layered approach, combining fasting measures, calculated indices and dynamic testing 2.
An insulin resistance test panel groups these metabolic markers into one draw, and the collection details and interpretation notes sit on that page rather than here.
Two practical points are worth carrying into any appointment. First, insulin assays differ between laboratories, so comparing a result from one lab against a result from another is less reliable than comparing two results from the same lab. Second, a single draw is a snapshot. A trend across two or three draws, taken under similar conditions, carries more information than any one number.
The most informative companions are the glucose markers, the androgen markers and SHBG, because together they describe both ends of the loop described above. The table below sets out what each one measures and why it tends to appear on a workup in this context.
| Marker | What it measures | Why it appears on a PCOS workup |
|---|---|---|
| Fasting glucose | Blood sugar after an overnight fast | Can read ordinary while insulin is already elevated, so it is read with insulin rather than alone |
| HbA1c | Average glucose exposure over recent months | Gives a slower moving view that is less affected by a single day |
| HOMA-IR | An index calculated from fasting glucose and insulin | Summarises the pair as one trackable number across repeat draws |
| Total testosterone | All circulating testosterone, bound and free | Part of the androgen picture, though it can look ordinary when SHBG is low |
| SHBG | The carrier protein that binds sex hormones | Determines how much testosterone circulates in free, active form |
| Free testosterone or free androgen index | The unbound, active fraction | Tracks androgen activity at tissues more closely than the total |
| LH and FSH | Pituitary signals to the ovary | Standard part of cycle assessment and ovarian function review |
| AMH | A marker reflecting follicle numbers | Reviewed by clinicians during assessment of ovarian activity |
| Triglycerides and HDL cholesterol | Circulating lipids | Part of the wider metabolic picture that clinicians review over time |
| TSH and prolactin | Thyroid and pituitary function | Often checked because other conditions can also disrupt cycles |
Ranges for every marker in this table vary by lab, age and sex, and no single value in it defines a condition. The point of running them together is pattern recognition. For example, a total testosterone sitting mid range alongside a low SHBG tells a different story than the same total testosterone with a healthy SHBG, because higher insulin is associated with lower SHBG and therefore a larger free fraction 3.
A fasting insulin above the typical range usually reflects a pancreas working harder than average to keep glucose in range, which is the signature of reduced insulin sensitivity. It is an observation, not a diagnosis, and it is read alongside glucose rather than instead of it.
Walking through it in order helps. The observation is a number above the range printed on your report. What it may reflect is compensation, meaning more insulin is being released for the same glucose control. It may also reflect something about the draw itself, such as an incomplete fast, an acute illness or a very poor night of sleep. The next step is to confirm the pattern with a repeat draw under similar conditions and to review it with a clinician alongside glucose, HbA1c and the androgen markers.
An ordinary fasting insulin does not close the question. Fasting measures describe the resting state, and some people hold a normal fasting value while mounting a much larger insulin response after eating, which is why dynamic testing with insulin measured during a glucose challenge is sometimes used. A normal result alongside persistent symptoms is a reason to keep asking questions, not a reason to stop.
Where fasting insulin is clearly suboptimal and glucose or HbA1c is also outside the standard range, that combination is worth discussing with a clinician promptly rather than at the next routine appointment. Never set an abnormal result aside because a single other marker looked fine.
Several everyday factors can shift a fasting insulin value enough to change how it reads, which is why one result is a snapshot rather than a verdict.
The most common is the fast itself. An incomplete fast, a late or unusually large meal the night before, or juice and milky coffee on the way to the lab all raise insulin. Acute illness and infection can move it. A short or badly broken night of sleep can reduce insulin sensitivity temporarily. A very hard training session in the preceding day can shift it in either direction depending on timing. Acute stress in the hours before the draw is another variable that is easy to overlook.
Some medicines also influence glucose and insulin. If you take anything regularly, ask your prescriber whether it is relevant to your result before drawing conclusions from the number.
Two technical points round this out. Insulin assays are not standardised across laboratories, so the same sample can produce slightly different values in different labs. And the time of day matters, which is why fasting draws are usually scheduled in the morning. Keeping the conditions consistent between repeat tests is more useful than chasing a perfect single result.
It affects them mainly through androgens. Higher androgen activity within the ovary interferes with the orderly maturation of follicles, so ovulation becomes irregular or stops, and cycles lengthen or disappear.
The chain runs from insulin to androgen to follicle. Higher insulin is associated with elevated androgen levels in polycystic ovary syndrome 4, and the resulting androgen excess is one of the features most closely tied to disrupted ovarian function in descriptions of the condition's mechanism 3. Lower SHBG compounds the effect by increasing the free fraction of testosterone reaching tissues.
For someone tracking cycles, this explains a frustrating pattern. Cycle length can vary widely month to month, ovulation predictor results can be ambiguous, and luteal phases can be short or absent. These are downstream consequences rather than independent problems.
The main ones are glucose regulation and lipids, tracked over years rather than months. Polycystic ovary syndrome is associated with long term metabolic consequences, including impaired glucose tolerance, type 2 diabetes and disordered lipids 7.
This is the strongest argument for testing earlier rather than later. The condition is increasingly described as a metabolic condition as much as a reproductive one, with insulin resistance as a central thread running through both presentations 1. Framed that way, a metabolic panel is not an optional extra alongside the hormone panel. It is half the assessment.
An association is not a prediction about you. Many people with the condition maintain stable glucose markers for decades. What the association supports is monitoring, so that a drift in HbA1c or fasting glucose is noticed as a trend rather than discovered years later as a surprise. Repeating the same markers at sensible intervals, in the same lab where possible, is what makes a trend visible.
FitScript's membership covers 150+ biomarkers tested per year, with results read in context by Atlas, FitScript's AI health advisor. How often any individual marker is worth repeating is a judgement for the clinician who knows your history.
Diet is one of the factors examined most often in relation to insulin resistance in polycystic ovary syndrome, and research suggests that dietary change can influence measures of insulin resistance in this group 8. What that does not establish is a single eating pattern that fits every person with the condition.
It is worth separating two ideas that often get merged. One is the overall pattern of what someone eats and how their body composition changes over time. The other is the specific macronutrient split of a diet. These are not the same question, and conclusions about one do not transfer automatically to the other.
This page does not give dietary advice, and nothing here should be read as a recommendation to adopt or avoid any particular way of eating. Food choices interact with cycle symptoms, mental health, medical history and practical life in ways that a general article cannot account for. A clinician or a qualified professional looking at your own results is the right place to work out what, if anything, should change.
What testing adds to that conversation is a baseline. Without insulin, glucose and SHBG measured before a change, there is no way to tell later whether anything moved. With them, the conversation has numbers in it rather than impressions.
It is worth talking to a clinician whenever symptoms persist or a result sits outside the range on your report, and promptly when glucose markers and insulin are both suboptimal at the same draw.
Specific situations worth raising include cycles that have been irregular or absent for several months, androgen related skin or hair changes that are new or worsening, a fasting insulin or HbA1c outside the standard range, or darkened velvety skin in body folds. A family history of type 2 diabetes alongside any of these strengthens the case for a metabolic panel rather than a reproductive panel alone.
Bring the actual report rather than a summary, including the reference ranges your lab printed, the date and whether you were fasted. If you have older results, bring those too, because the direction of change is often more informative than any single value.
This article is educational and is not medical advice. Discuss your results and any treatment with a clinician or licensed provider, and remember that treatment decisions belong to a licensed provider who has evaluated you personally.
For more on the metabolic side of this picture, how to reverse insulin resistance looks at what the markers can show over time, and how to lose weight with insulin resistance covers why the usual advice often lands differently when insulin is elevated.
No. Reduced insulin sensitivity is common in polycystic ovary syndrome, but it is not universal, and it varies a great deal in degree between individuals. The only way to know where you sit is to measure insulin and glucose together rather than assume from symptoms or body weight.
Yes, and this is one of the main reasons insulin is measured at all. The pancreas can release extra insulin for years to keep glucose inside the standard range, so a normal fasting glucose can sit on top of an elevated insulin value. Testing both at the same draw is what makes that visible.
It is a useful starting point but rarely sufficient by itself. It is usually read alongside fasting glucose, HbA1c, androgen markers and SHBG, because those together describe both the metabolic and the hormonal side of the picture. Your clinician decides which combination makes sense for your situation.
Yes, a fasting insulin test requires an overnight fast, typically with water only. Coffee with milk, juice or a small snack on the way to the lab can all change the result. Follow the specific instructions your lab or clinician gives you, since requirements differ slightly between providers.
Yes. Body weight is not a reliable filter for who should be tested, and people at a lean body weight can show reduced insulin sensitivity. If you have the symptom picture but have been told your weight rules it out, it is reasonable to ask for the numbers rather than rely on the assumption.
Higher insulin can push the ovary toward producing more androgen, and more androgen activity can interfere with the orderly maturation of follicles. When that happens, ovulation becomes irregular or stops, and cycles lengthen or disappear. This is why a cycle problem and a metabolic marker can be two views of the same underlying pattern.
There is no single interval that suits everyone. The useful principle is consistency, meaning repeat draws under similar conditions at the same lab so that a trend is readable. How often that should happen for you is a decision for the clinician who knows your history and your previous results.
Treat it as information to bring to a clinician, not as a diagnosis. Note your fasting status, any recent illness, poor sleep or hard training, and bring the full report with its printed reference ranges. A repeat draw under similar conditions often clarifies whether the value reflects a pattern or a one-off, and your provider decides what, if anything, comes next.